Jean Powers

942 total citations
12 papers, 748 citations indexed

About

Jean Powers is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean Powers has authored 12 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean Powers's work include Biomarkers in Disease Mechanisms (4 papers), Clusterin in disease pathology (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Jean Powers is often cited by papers focused on Biomarkers in Disease Mechanisms (4 papers), Clusterin in disease pathology (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Jean Powers collaborates with scholars based in Canada, Cameroon and Japan. Jean Powers's co-authors include Elizabeth A. Eisenhauer, Dongsheng Tu, Kim N., Martin Gleave, Ladan Fazli, Edward C. Jones, S. Larry Goldenberg, Sébastien J. Hotte, Scott North and Wendy Walsh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jean Powers

11 papers receiving 733 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean Powers Canada	9	420	330	265	209	81	12	748
Loredana Militello Italy	9	355 0.8×	319 1.0×	197 0.7×	205 1.0×	106 1.3×	19	746
Suso Platero United States	11	615 1.5×	441 1.3×	301 1.1×	309 1.5×	68 0.8×	22	1.1k
Raul Ayala United States	9	483 1.1×	356 1.1×	253 1.0×	124 0.6×	55 0.7×	18	830
M. Beeram United States	16	406 1.0×	452 1.4×	304 1.1×	169 0.8×	58 0.7×	48	860
Harald Hugenschmidt Norway	11	384 0.9×	417 1.3×	189 0.7×	267 1.3×	107 1.3×	13	826
Arnaud Guillé France	15	458 1.1×	312 0.9×	158 0.6×	353 1.7×	49 0.6×	42	856
María Luisa Botero United States	5	538 1.3×	322 1.0×	176 0.7×	204 1.0×	54 0.7×	11	844
Marie‐Paule Sablin France	18	410 1.0×	499 1.5×	289 1.1×	354 1.7×	89 1.1×	50	942
Alexandra Florin Germany	19	691 1.6×	388 1.2×	186 0.7×	302 1.4×	123 1.5×	27	1.1k
Haby Henary United States	14	376 0.9×	378 1.1×	199 0.8×	117 0.6×	57 0.7×	32	702

Countries citing papers authored by Jean Powers

Since Specialization

Citations

This map shows the geographic impact of Jean Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Powers more than expected).

Fields of papers citing papers by Jean Powers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Powers. The network helps show where Jean Powers may publish in the future.

Co-authorship network of co-authors of Jean Powers

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Powers. A scholar is included among the top collaborators of Jean Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Powers. Jean Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Powers, Jean, et al.. (2016). Predominance of N-acetyl transferase 2 slow acetylator alleles in children less than ten years experiencing adverse treatment events following artemisinin-based combination therapy in North and South West Regions of Cameroon. AFRICAN JOURNAL OF BIOTECHNOLOGY. 15(25). 1285–1291.

Pitz, Marshall, Elizabeth A. Eisenhauer, Mary MacNeil, et al.. (2015). Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology. 17(9). 1270–4. 96 indexed citations

Eigl, Bernhard J., Scott North, Nevin Murray, et al.. (2011). Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).. Molecular Cancer Therapeutics. 10(11_Supplement). A221–A221. 1 indexed citations

N., Kim, Sébastien J. Hotte, Evan Y. Yu, et al.. (2010). Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(27). 4247–4254. 179 indexed citations

Chen, Eric X., Derek J. Jonker, Isabelle Gauthier, et al.. (2009). Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Clinical Cancer Research. 15(4). 1481–1486. 34 indexed citations

Chia, Stephen, Susan Dent, Susan Ellard, et al.. (2009). Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer. Clinical Cancer Research. 15(2). 708–713. 41 indexed citations

N., Kim, Lillian L. Siu, Hal Hirte, et al.. (2008). A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research. 14(3). 833–839. 95 indexed citations

N., Kim, Elizabeth A. Eisenhauer, Ladan Fazli, et al.. (2005). A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer. JNCI Journal of the National Cancer Institute. 97(17). 1287–1296. 216 indexed citations

Gelmon, Karen A., Karl Bélanger, Denis Soulières, et al.. (2005). A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130. Investigational New Drugs. 23(5). 445–453. 5 indexed citations

10.

Winquist, Eric, Malcolm J. Moore, Kim N., et al.. (2005). A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer☆. Urologic Oncology Seminars and Original Investigations. 23(3). 143–149. 44 indexed citations

11.

Belch, Andrew, C. Tom Kouroukis, Michael Crump, et al.. (2004). Phase II Trial of Bortezomib in Mantle Cell Lymphoma.. Blood. 104(11). 608–608. 27 indexed citations

12.

Chen, Christine I., Darrell White, C. Tom Kouroukis, et al.. (2004). Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).. Blood. 104(11). 3278–3278. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact